

L Number	Hits	Search Text	DB	Time stamp
1	28849	RESTENOSIS OR STENOSIS	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:06
2	13848	VEGF\$5 or (Vascular ADJ endothelial)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:05
3	602	(RESTENOSIS OR STENOSIS ) SAME (VEGF\$5 or (Vascular ADJ endothelial) )	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:04
4	59	Alitalo NEAR Kari	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:04
5	20	(Alitalo NEAR Kari ) and (gene ADJ therapy)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:04
6	498	(VEGF\$5 or (Vascular ADJ endothelial) ) SAME adenovir\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:05
7	22	(VEGF-D VEGF-C) SAME adenovir\$5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:05
8	19297	RESTENOSIS	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:07
9	3063	RESTENOSIS and (VEGF\$5 or (Vascular ADJ endothelial) )	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:06
10	555	RESTENOSIS SAME (VEGF\$5 or (Vascular ADJ endothelial) )	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:06
11	1368	RESTENOSIS and (VEGF\$5 or (Vascular ADJ endothelial) ) and adenovir\$6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:07
12	1095	(RESTENOSIS and (VEGF\$5 or (Vascular ADJ endothelial) ) and adenovir\$6) and gene ADJ therapy	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:07
13	2583	RESTENOSIS.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:07
14	0	(RESTENOSIS SAME adenovir\$6 SAME vegf\$3).clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:08
15	7	(RESTENOSIS AND adenovir\$6 AND vegf\$3).clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/19 11:08

=> d his

(FILE 'HOME' ENTERED AT 11:13:10 ON 19 JUL 2004)

FILE 'MEDLINE' ENTERED AT 11:13:20 ON 19 JUL 2004

L1 9221 S RESTENOSIS  
L2 309 S VEGF-C OR VEGF(W)C  
L3 3 S L1 (L) L2  
L4 3 DUP REM L3 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED AT 11:15:09 ON 19 JUL 2004

L5 12 S L3  
L6 6 DUP REM L5 (6 DUPLICATES REMOVED)  
L7 6 SORT L6 PY

=> d an ti so au ab pi 17 1-6

L7 ANSWER 1 OF 6 MEDLINE on STN  
AN 2000507205 MEDLINE  
TI Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta.  
SO Circulation, (2000 Oct 31) 102 (18) 2262-8.  
Journal code: 0147763. ISSN: 1524-4539.  
AU Hiltunen M O; Laitinen M; Turunen M P; Jeltsch M; Hartikainen J; Rissanen T T; Laukkonen J; Niemi M; Kossila M; Hakkinen T P; Kivela A; Enholm B; Mansukoski H; Turunen A M; Alitalo K; Yla-Herttuala S  
AB BACKGROUND: Gene transfer to the vessel wall may provide new possibilities for the treatment of vascular disorders, such as postangioplasty **restenosis**. In this study, we analyzed the effects of adenovirus-mediated vascular endothelial growth factor (**VEGF**)-C gene transfer on neointima formation after endothelial denudation in rabbits. For comparison, a second group was treated with VEGF-A adenovirus and a third group with lacZ adenovirus. Clinical-grade adenoviruses were used for the study. METHODS AND RESULTS: Aortas of cholesterol-fed New Zealand White rabbits were balloon-denuded, and gene transfer was performed 3 days later. Animals were euthanized 2 and 4 weeks after the gene transfer, and intima/media ratio (I/M), histology, and cell proliferation were analyzed. Two weeks after the gene transfer, I/M in the lacZ-transfected control group was 0. 57+/-0.04. **VEGF**-C gene transfer reduced I/M to 0.38+/-0.02 (P:<0.05 versus lacZ group). I/M in VEGF-A-treated animals was 0.49+/-0.17 (P:=NS). The tendency that both VEGF groups had smaller I/M persisted at the 4-week time point, when the lacZ group had an I/M of 0.73+/-0.16, the VEGF-C group 0.44+/-0.14, and the VEGF-A group 0.63+/-0.21 (P:=NS). Expression of VEGF receptors 1, 2, and 3 was detected in the vessel wall by immunocytochemistry and in situ hybridization. As an additional control, the effect of adenovirus on cell proliferation was analyzed by performing gene transfer to intact aorta without endothelial denudation. No differences were seen in smooth muscle cell proliferation or I/M between lacZ adenovirus and 0.9% saline-treated animals. CONCLUSIONS: Adenovirus-mediated **VEGF-C** gene transfer may be useful for the treatment of postangioplasty **restenosis** and vessel wall thickening after vascular manipulations.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:290851 CAPLUS  
DN 132:318341  
TI Use of **VEGF-C** or VEGF-D gene or protein to prevent **restenosis**  
SO PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
IN Yla-Herttuala, Seppo; Alitalo, Kari; Hiltunen, Mikko O.; Jeltsch, Markku M.; Achen, Marc G.  
AB The present invention provides materials and methods for preventing stenosis or **restenosis** of a blood vessel using Vascular Endothelial Growth Factor C (**VEGF-C**) and/or Vascular Endothelial Growth Factor D (**VEGF-D**) genes or proteins. A medical device

designed to contact a surface of a blood vessel in the course of surgery to treat stenosis of the blood vessel is also claimed, the device characterized by an improvement comprising integrating into the device a composition effective to prevent **restenosis**, said composition comprising at least one anti-**restenosis** agent selected from the group consisting of a VEGF-C polynucleotide, a VEGF  
-C polypeptide, a VEGF-D polynucleotide, and a VEGF-D polypeptide. The medical device is selected from the group consisting of intravascular stents, intravascular catheters, extravascular collars, elastomeric membranes adapted to cover a surface of an intravascular stent or catheter, and combinations thereof. Also claimed is a kit for treating **restenosis** comprising a container holding at least one anti-**restenosis** agent of the invention and a label attached to or packaged with the container, the label describing use of the compound for prevention of **restenosis** of a blood vessel. The kit further comprises a medical device of the invention.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000024412	A2	20000504	WO 1999-US24054	19991026
WO 2000024412	A3	20000803		
W: AU, CA, CN, JP, NO, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2340593	AA	20000504	CA 1999-2340593	19991026
EP 1126870	A2	20010829	EP 1999-956559	19991026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 510121	A	20030228	NZ 1999-510121	19991026
AU 768330	B2	20031211	AU 2000-13147	19991026
NO 2001002017	A	20010626	NO 2001-2017	20010424

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:545508 CAPLUS

DN 135:132464

TI Cyclic peptide inhibitors of VEGF, VEGF-C, and VEGF-D, preparation methods, pharmaceutical compositions, and therapeutic use

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

IN Achen, Marc G.; Hughes, Richard A.; Stacker, Steven; Cendron, Angela

AB The invention provides monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, e.g. loop 1, loop 2 or loop 3 of VEGF-D, as well as methods of making them, pharmaceutical compns. containing them, and therapeutic methods of use.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001052875	A1	20010726	WO 2001-US1533	20010118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065218	A1	20020530	US 2001-761636	20010118
EP 1248642	A1	20021016	EP 2001-942559	20010118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				